A far-reaching analysis and segmentation of the colorectal cancer therapeutics market in APAC by end-user (small molecules and biologics), by route of administration (oral and parenteral), and by lines of chemotherapy (first-line chemotherapy and second-line chemotherapy). Amgen, Bayer Healthcare, Bristol-Myers Squibb, Chugai Pharmaceutical, Merck, and Sanofi are the leading vendors analyzed in the report.
Technavio has released updated information on the cancer therapeutics market, with the publication of its new market research report, colorectal cancer therapeutics market in APAC. The colorectal cancer therapeutics market in APAC is expected to grow at a CAGR of 6% between 2015 and 2019. At present, the available therapies are not enough to cure colorectal cancer; however, the survival rates in patients can be extended.
“One of the interesting trends that this market is witnessing is the growing use of biologics in treating colorectal cancer. Biologics are targeted therapies, which act only on the malignant cells and do not destroy the healthy cells. Avastin (bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab) and Zaltrap (ziv-Aflibercept) are some of the major biological drugs used to treat colorectal cancer,” says Brahadeesh Chandrasekaran, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
Colorectal cancers cannot be cured completely by the currently available therapies and if it has not metastasized, surgery would be the only treatment option. As a result, a drug manufacturer has immense opportunities to exploit and seek a favorable position in the market by developing appropriate drugs and mitigate this issue.
The leading vendors in the colorectal cancer therapeutics market in APAC are Amgen, Bayer Healthcare, Bristol-Myers Squibb, Chugai Pharmaceutical, Merck, and Sanofi. The market is witnessing moderate growth because of a rise in the prevalence of colorectal cancer and unmet medical needs. Therefore, companies that manufacture and market drugs that can treat colorectal cancer effectively and cure, besides exhibiting a high safety and efficacy profile, are expected to gain a competitive edge over other companies in this market.
A more detailed analysis is available in the Technavio report, Colorectal Cancer Therapeutics Market in APAC 2015-2019.
We can customize this reports by other regions and specific segments upon request.
Other related reports:
